High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. [electronic resource]
Producer: 20110321Description: 107-14 p. digitalISSN:- 1573-7217
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- blood
- Breast Neoplasms -- blood
- Capecitabine
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Chi-Square Distribution
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Enzyme-Linked Immunosorbent Assay
- Female
- Fluorouracil -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Lapatinib
- Logistic Models
- Middle Aged
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- metabolism
- Republic of Korea
- Risk Assessment
- Risk Factors
- Time Factors
- Transforming Growth Factor alpha -- blood
- Treatment Outcome
- Up-Regulation
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.